RE:RE:RE:Guggenheim raises Merck US (MSD) to a buy on KeytrudaSeamus Fernandez Senior Managing Director of Guggenheim's Healthcare Research team specifically made note that Keytuda PD-1 in an I/O combination “would be a substantial value-enhancing event”, and that was a significant reason for the the firm's BUY recommendation. Unlike you, that's plenty enough substantiation for those in the know!